A non-invasive prenatal test that analyzes fetal DNA from maternal blood using Next Generation Sequencing (NGS) technology. The test can be performed as early as 10 weeks of pregnancy with detection rates exceeding 99% accuracy. It is the first in Korea to analyze chromosomes 9, 16, and 22, as well ...
Manufactured by
Eone-Diagnomics Genome Center
South Korea
Global NGS Company, EDGCWe provide the value for a healthy lifestyle by suggesting customized healthcare based on genome information.Through genome analysis, we have provided genetic screening tests to help people predict cancer and diseases and to offer personalized healthcare.We have developed cutting-edge diagnostic solutions that empower individuals to make informed health decisions.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Genes 2Me Private Ltd
India · 1 relevant product
Shenzhen Salus BioMed Co., Ltd.
China · 3 relevant products
Origin Biotechnology Co., Ltd.
Taiwan · 11 relevant products
54 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →18 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
3 of 99 closest product alternatives
Genes 2Me Private Ltd · India
Next generation sequencing panel for non-invasive prenatal testing (NIPT) and newborn screening (NBS). Provides precision genetic profiling for maternal and pediatric healthcare applications.
Shenzhen Salus BioMed Co., Ltd. · China
NIPT is a prenatal screening method that uses high-throughput gene sequencing and molecular genetic techniques to detect fetal cell-free DNA fragments in maternal peripheral blood, assessing the risk of common fetal chromosomal aneuploidies (T21, T18, T13). The test extracts free DNA from maternal blood containing fetal genetic information and analyzes it through high-throughput sequencing to detect abnormalities in fetal chromosome number and structure. Compared to traditional maternal serum screening, NIPT offers advantages of high detection rate and low false positive rate, while avoiding the risks associated with invasive methods such as amniocentesis.
Origin Biotechnology Co., Ltd. · Taiwan
A molecular medicine-based screening test for prenatal diagnosis and prevention of genetic abnormalities. The test provides rapid results to support clinical decision-making in maternal-fetal medicine.
96 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products